NCT04704271 Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
| NCT ID | NCT04704271 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Yale University |
| Condition | Cannabis |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2019-10-09 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 100 participants in total. It began in 2019-10-09 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Eligibility Criteria
Inclusion Criteria: * At least one lifetime exposure to cannabis * Good physical and mental health Exclusion Criteria: * Cannabis naïve individuals * Major current or recent stressors
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04704271 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Cannabis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04704271 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT04704271 currently recruiting?
Yes, NCT04704271 is actively recruiting participants. Contact the research team at carly.hewes@yale.edu for enrollment information.
Where is the NCT04704271 trial being conducted?
This trial is being conducted at West Haven, United States.
Who is sponsoring the NCT04704271 clinical trial?
NCT04704271 is sponsored by Yale University. The trial plans to enroll 100 participants.